GW Pharmaceuticals plc
https://www.gwpharm.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GW Pharmaceuticals plc
First Oral Treatment For Spinal Muscular Atrophy Gets EMA Nod
New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.
UK Biotechs Look Destined To Remain Bit Players
Another promising British-based company, GW Pharma, has been acquired, this time by mid-sized US player Jazz. Is it a pipedream that a UK biotech could be in a position to pull off a $7bn takeover of its own or does it really not matter?
Jazz Wades Into Cannabinoid Weeds With $7.2bn GW Buy
Priced at a 50% premium to GW’s value, the deal will reduce the percentage of Jazz’s drug sales coming from Xyrem, provide double-digit revenue growth and expand the R&D pipeline to 19 programs.
GW Pharma Soars On Strong Epidiolex Sales
With its lead cannabinoid product Epidiolex continuing to advance, the London-headquartered, NASDAQ-listed firm has begun late-stage trials in the US with nabiximols, which looks likely to become its second approved drug.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Greenwich Biosciences, Inc.